肝细胞生长因子及其受体在子宫内膜癌组织中的表达及其意义被引量：4

The expression and significance of hepatocytegrowth factor and c-Met receptor in endometrial carcinoma

下载PDF

导出

摘要目的 :研究肝细胞生长因子HGF及其受体c-Met在子宫内膜癌组织中的表达及其与子宫内膜癌手术病理分期、病理分级的关系。方法 :采用免疫组织化学S -P法 ,检测 5 2例子宫内膜腺癌、12例正常子宫内膜组织中HGF及其受体c -Met的表达 ,并结合肿瘤的手术病理分期、病理分级 ,对结果进行 χ2 检验、Fisher精确概率法等统计分析 ,从而判断其价值。结果 :子宫内膜癌组织中HGF及c -Met表达较正常子宫内膜组织明显增高 ;子宫内膜癌的期别越晚、分化越差 ,c -Met表达越强。结论 :HGF、c -Met的过度表达与子宫内膜癌的发生发展有关 ;c -Met与子宫内膜癌的手术病理分期、病理分级密切相关。 Objective:To investigate the expression and significance of hcpatocyte growth factor (HGF) and c-Met,receptor (c-Met) in endometrial carcimoma.Methods:Using S-P immunohistochemistry method,the expression of HGF and c-Met in the specimens of 52 cases with endometrial catcmoma and 16 cases with normal endometrium was examined.Then the correlation was analyzed between the two factors and the stage and differentiation of EC.Results:The expressions of HGF and c-Met in endometrial carcinoma were significantly higher than in normal endometrium.The expression of c-Met was closely associated with the stage and differentiation of endometrial carcinoma.Conclusion:Overexpression of HGF and c-Met facilitates the malignant progress of endometrium,c-Met is associated with the prognosis of EC.

作者肖琳唐良萏

机构地区重庆医科大学临床学院妇产科

出处《重庆医科大学学报》 CAS CSCD 2004年第6期789-791,共3页 Journal of Chongqing Medical University

关键词子宫内膜癌肝细胞生长因子免疫组织化学 Endometrial carcinoma (EC) Hepatocyte growth factor (HGF) Immunohistochemistry

分类号 R329.27 [医药卫生—人体解剖和组织胚胎学] R737 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1Kataoka H, Hamasuna R. Pericellular activation of hepatocyte growth factor/scatter factor(HGF/SF) in colorectal carcinomas:roles of HGF activator(HGFA) and HGFA inhibitor type 1(HAI- 1)[J].Hum Cell,2001;14(1):83-93.
2Parr C, Davies G, Nakamura T, et al. The HGF/SF mduced phosphorylation of paxillin, matrix adhesion, and invasion of prostate cancer cells were suppressed by NK4, an HGF/SF variant[J]. Biochem Biophys Res Commun, 2001; 285 ( 5 ):1330- 1337.
3Maulik G, Shrikhandc A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c - Met, in oncogenesis and potential for therapeutic inhibition [J]. Cytokine Growth Factor Rev,2002;13(1):41-59.
4To CT, Tsao MS. The role ofhepatocyte growth factor/scatter factor and met receptor in human crow, ers[J]. Oncol Rep, 1998 ;5(5): 1013 - 1024.
5Yano H, Hara A, Murase S, et al. Expression of hepatocyte growth factor and matrix metalloproteinase - 2 in human glioma[J]. Bram Tumor Pathol, 2001; 18 ( 1 ): 7 - 12.
6Okusa Y, Ichikura T, Mochizuki H, et al. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines[J]. Int J Oncol, 2000; 17 (5):1001 - 1005.
7Jin L, Fuchs A, Schnitt SJ, et al. Expression of Scatter Factor and c- met Receptor in Benign and Malignant Breast Tissue[J]. Cancer, 1997;79(4) :749-760.
8Wagatsuma S, Konno R, Sato S, et al. Tumor Angiogensis,Hepatocyte Growth Factor, and c- Met Eepression in Endometrial Carcinoma[J]. Cancer, 1998; 82 (3): 520-529.
9Date K, Matstumoto K, Shimura H, et al. HGF/NK4hepatocyte growth factor[J]. FEBS Lett, 1997; 420 ( 1 ): 1 - 6.
10Hiscox S,Parr C, Nakamura T, et al. Inhibition of HGF/SF- induced breast cancer cell motility and invasion by the HGF/SF variant, NK4 [J]. Breast Cancer Res Treat, 2000; 59(3) :245 -254.